Objective-A role for thrombin in the pathogenesis of atherosclerosis has been suggested through clinical and experimental studies revealing a critical link between the coagulation system and inflammation. Although approved drugs for inhibition of thrombin and thrombin-related signaling have demonstrated efficacy, their clinical application to this end may be limited because of significant potential for bleeding side effects. Thus, we sought to implement a plaque-localizing nanoparticle-based approach to interdict thrombin-induced inflammation and hypercoagulability in atherosclerosis. Approach and Results-We deployed a novel magnetic resonance spectroscopic method to quantify the severity of endothelial damage for correlation with traditional metrics of vessel procoagulant activity after dye-laser injury in fat-fed apolipoprotein E-null mice. We demonstrate that a 1-month course of treatment with antithrombin nanoparticles carrying the potent thrombin inhibitor PPACK (d-phenylalanyl-l-prolyl-l-arginyl chloromethylketone) nanoparticle (1) reduces the expression and secretion of proinflammatory and procoagulant molecules, (2) diminishes plaque procoagulant activity without the need for systemic anticoagulation, (3) rapidly restores disrupted vascular endothelial barriers, and (4) retards plaque progression in lesion-prone areas. Conclusions-These observations illustrate the role of thrombin as a pleiotropic atherogenic molecule under conditions of hypercholesterolemia and suggest the utility of its inhibition with locally acting antithrombin nanoparticle therapeutics as a rapid-acting anti-inflammatory strategy in atherosclerosis to reduce thrombotic risk. (Arterioscler Thromb Vasc Biol. 2016;36:446-455. (J.W.M.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A therosclerosis, the leading cause of death in the Western world, is essentially a disease of inflammation from its inception through the evolution of vulnerable atheromas that eventually break down to induce focally occlusive thrombosis with consequential tissue death in subtended vascular beds. 1 A direct link exists between inflammation and coagulation in atherosclerosis by way of the serine protease thrombin that plays a central role in both clot formation and inflammatory molecular signaling events that may instigate and potentiate plaque development. [2] [3] [4] Thrombin's vascular activity is mediated primarily by a family of G-protein coupled receptors known as protease-activated receptors (PARs). 5 Activation of PAR-1 by thrombin initiates a signaling cascade that promotes proinflammatory, vasomotor, and cellular proliferative effects in various cell types, including endothelial cells, smooth muscle cells, and macrophages, among others. Thrombin signaling promotes the synthesis and release of procoagulant factors, such as tissue factor, which establishes the conditions for repeated cycles of endothelial disruption, coagulation, inflammation, and plaque expansion. 6 Given the abundance of thrombin in atherosclerotic plaques and its recognized contribution to plaque inflammation and hypercoagulability, 7, 8 we sought to investigate the hypothesis that focal inhibition of plaque thrombin to abrogate its inflammatory signaling actions would both attenuate plaque procoagulant activity and facilitate restoration of naturally anticoagulant endothelial vascular barriers. Furthermore, we sought to elucidate direct relationships between thrombin inhibition, regulation of inflammatory signaling, recovery of endothelial barriers, and reduction in thrombotic risk with the use of clinically translatable functional methods for quantifying vascular barrier integrity. Although clinically approved antithrombotic pharmaceuticals have been evaluated in experimental primary and clinical
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Rohun U. Palekar, Andrew P. Jallouk, Jacob W. Myerson, Hua Pan, Samuel A. Wickline secondary prevention trials, 9 no information exists as to their ability to directly attenuate focal plaque thrombotic propensity or to improve vascular barrier integrity, which could serve to deter acute vascular syndromes.
To those ends, we have reported recently that atherosclerotic endothelial damage can be quantified nondestructively with the in vivo use of semipermeant perfluorocarbon (PFC)-core nanoparticles that passively diffuse beyond disrupted endothelial barriers in plaques, allowing both fluorine ( 19 F) magnetic resonance imaging and quantification of PFC nanoparticle deposition with 19 F magnetic resonance spectroscopy. 10 Using this method, we have delineated the temporal progression of endothelial barrier disruption in apolipoprotein E (ApoE)-null mice as a consequence of a prolonged high-fat diet and demonstrated that barrier damage was related directly to the propensity for thrombotic occlusion in the dye-laser vessel injury model. Moreover, dietary management by restoration of a normal chow diet simultaneously recovered vascular barrier integrity and rapidly reduced plaque hypercoagulability within 1 to 2 months. 11 Although these nanoparticles previously have been conjugated to selected antithrombin agents to serve as potent and safe antagonists of thrombosis in acute clotting events, 12, 13 their therapeutic potential for chronic control of inflammatory signaling through thrombin inhibition is untested in atherosclerosis.
Accordingly, we hypothesize that the reported capability of PFC nanoparticle to localize to atherosclerotic plaques manifesting disrupted barriers and be retained for prolonged periods 10, 11 would set the stage for the formulation and focal deposition of a reservoir of antithrombin nanoparticles in plaques ( Figure 1A ) to exert prolonged surveillance against and rapid inactivation of any locally generated thrombin. The present work was designed to examine the efficacy and safety of nanoparticle-based strategies for focal inhibition of serine proteases, namely thrombin ( Figure 1A ) in atherosclerosis. The test agent used for this study is a PFC nanoparticle carrying the potent thrombin inhibitor d-phenylalanyl-l-prolyl-l-arginyl chloromethylketone (PPACK), which has been previously demonstrated to be efficacious in limiting the growth of acute thrombi in mouse models of carotid artery thrombosis, with limited bleeding side effects. 12 Furthermore, PPACK itself is a highly potent inhibitor of thrombin with several orders of magnitude increased affinity for thrombin over other serine proteases. By delivering doses of antithrombin nanoparticles over the course of several weeks, we aim to define the role of focal thrombin inhibition in mediating inflammatory signaling events in vitro and in vivo how that might play a mechanistic role in diminishing vascular endothelial barrier damage and thrombotic risk. The observed efficacy of the approach indicates a significant direct contribution of thrombin signaling to the evolution of atherosclerosis and the emergence of thrombotic risk and implicates it as a key contributor to endothelial damage in this model.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Antithrombin Nanoparticles Reduce Vascular Procoagulant Activity In Vivo
To characterize the effects of PPACK nanoparticle on reducing procoagulant activity, groups of ApoE-null mice were fed a Western diet for 3 months followed by continuation of the diet with treatment (saline, control nanoparticle, and PPACK nanoparticle) for 1 additional month. At the conclusion of the treatment/feeding period, mice were subjected to a previously validated 11, 14, 15 model for measuring thrombotic risk using photochemical injury of the carotid artery that yields a quantitative metric of coagulant activity (vessel occlusion time) with good dynamic range and monotonic responsiveness to therapeutic agents that affect clotting. Before performing the vessel injury, mice were maintained on their diets for 2 to 3 additional days without further treatment to allow washout of any residual antithrombin nanoparticles. After 1 month of PPACK nanoparticle treatment, carotid occlusion times increased significantly over control groups (Figure 2A) , with occlusion times reaching 48.71±6.7 minutes (N=7) compared with saline treatment (26.11±4.63 minutes, N=9; P=0.005) and control nanoparticle treatment (25.55±4.17 minutes, N=9; P=0.004). We note that the occlusion times in the 1-month PPACK nanoparticle-treated group approximated those of previously reported fat-fed ApoE null mice after 2 months off diet, indicating that the PPACK nanoparticle therapy may more rapidly attenuate vessel procoagulant activity than does dietary management in this model, despite maintenance of the high-fat diet in the PPACK nanoparticle-treated group. 11
Antithrombin Nanoparticles Restore Vascular Barrier Integrity In Vivo
We tested the ability of PPACK nanoparticle treatment to restore functional endothelial barriers, which concomitantly might be expected to reduce plaque procoagulant activity as previously reported. 11 Mice were injected with a dose of crown ether nanoparticle for magnetic resonance spectroscopy that were allowed to circulate for 2 hours before killing, at which time plaque saturation occurs. 10 After this circulation time, the entire length of the aorta (from the aortic root to the bifurcation) was removed for ex vivo 19F magnetic resonance spectroscopy measurements at 11.7T. Figure 2B illustrates the beneficial effects of PPACK nanoparticle treatment for 1 month on plaque endothelial permeability according to the decreased deposition of crown ether nanoparticle (0.084±0.009 μL/g aorta, N=7) compared with saline (0.122±0.011 μL/g aorta, N=8; P=0.023) and control nanoparticle (0.132±0.013 μL/g aorta, N=10; P=0.014). Using paired samples, we observed an inverse correlation (R=−0.56; Figure consistent with our previous observation that thrombotic risk tracks with plaque permeability to PFC nanoparticle. A subset of mice was allocated for measurements of plaque extent in the aortic arch by conventional Sudan IV staining and computer-assisted planimetry. 16 Overall, PPACK nanoparticle treatment resulted in a 20.69% decrease in aortic arch plaque extent ( Figure 2C ): 40.24±3.21% plaque area for saline-treated mice (N=5) and 31.91±1.69% plaque area for PPACK nanoparticle-treated mice (N=7; P=0.03).
Antithrombin Nanoparticles Attenuate Inflammatory Signaling Molecules
PAR-1 Responses
To delineate molecular signaling events responsible for the beneficial effects of PPACK nanoparticle, cell culture studies were used to quantify the responses of activated endothelial and monocytic cell lines to thrombin inhibition. First, as thrombin's effect on cell types is mediated primarily by cleavage of the PAR-1 receptor on cell surfaces, 5 flow cytometry was used to determine the percentage of intact PAR-1 receptors that was left after treatment with thrombin in the various treatment groups. PPACK nanoparticle treatment completely prevented thrombin cleavage of PAR-1 receptors on human aortic endothelial cells (HAECs) compared with thrombin or thrombin/control nanoparticle groups, which manifested significantly decreased PAR-1 expression (N=3 for both groups; P=0.019 and P=0.000005, respectively) as compared with baseline ( Figure 3A ).
Tissue Factor Responses
Because PPACK nanoparticles successfully prevented PAR-1 activation, we tested the downstream signaling effects of PAR-1 activation related to inflammation and coagulation. Expression of tissue factor on the surface of HAECs and THP-1 monocytes in response to thrombin stimulation was assayed using a functional assay of measuring Factor Xa generation as a result of the presence of tissue factor/factor VIIa (TF/FVIIa) complexes. PPACK nanoparticle prevented thrombin-induced TF expression on the surface of both HAECs ( Figure 3B ) and THP-1 monocytes ( Figure 3C ), with no significant increase over baseline TF levels at both concentrations of thrombin used (1 and 4 U/mL). Whole excised aortic arch segments exhibited a marked reduction in TF-positive plaque area after PPACK nanoparticle treatment: 46.75±5.74% (N=3) in PPACK-treated mice ( Figure 3D ) versus 72.69±5.06% (N=3; P=0.027) for saline treatment and 72.52±4.34% (N=3; P=0.023) for control nanoparticle treatment as quantified in immunofluorescent staining using ImageJ ( Figure 3E-3G ).
NF-kB Responses
Because thrombin is known to stimulate nuclear factor kappa B (NF-kB) transcriptional regulation of a panoply of inflammatory genes through PAR-1 signaling, we delineated the effect of PPACK nanoparticle on the inhibition of NF-kB activation in HAEC ( Figure 4A -4E) and THP-1 cells ( Figure 4F -4J). Thrombin cleavage of PAR-1 results in the activation of Gα q and dissociation of the Gβ γ complex, which subsequently results in the parallel activation of protein kinase C (PKC) σ and PI3-kinase/Akt pathways. These parallel pathways then converge to stimulate IKK (I kappa B kinase), which results in the binding of the p65 homodimer to IκB and subsequent phosphorylation and degradation of IκB. Activation of the PKCσ pathway results in activation of p38 which, in turn, phosphorylates p65 to induce the nuclear translocation and transcriptional activity of the p65. 17 Cell cultures were stained for phosphorylated p65 after 6 hours of thrombin stimulation and treatment. Treatment with PPACK nanoparticle resulted in little to no observable positive staining for intracellular phospho-p65 and preservation of IkB protein ( Figure II in the online-only Data Supplement) compared with thrombin and thrombin/control nanoparticle treatment groups. The preservation of IkB indicates that this cytoplasmic regulatory component of p65/p50 retains control of the preexisting cytoplasmic stores of p65, thereby preventing subsequent p65 phosphorylation and translocation to the nucleus.
Next we quantified phosphorylated NF-kB p65 (pp65) in the endothelium ( Figure 4K ) and intraplaque regions (Figure 4 L) by staining sections of the excised aortic arch for pp65 ( Figure 4M-4O) , where increased phosphorylation of p65 indicates increased NF-kB activity. After PPACK nanoparticle treatment, aortic plaques exhibited significantly decreased endothelial pp65 (11.49±3.66%, N=3) compared with saline (33.11±4.05%, N=3; P=0.017) and control nanoparticle treatments (33.25±4.33%, N=3; P=0.019). Decreased pp65 also was observed in the same regions as plaque macrophages after PPACK nanoparticle treatment (21.78±3.15%, N=3) compared with saline (43.31±6.55%, N=3) and control nanoparticle treatments (47.51±4.59%, N=3). To rule out loss of endothelial pp65 staining because of missing endothelium, selected neighboring slide sections where pp65 was noted to be reduced were stained for vWF (von Willebrand factor), indicating that endothelium was present, thus confirming the specificity for NF-kB downregulation by PPACK nanoparticle in endothelium in vivo ( Figure 4P-4R) .
Systemic Coagulation and Inflammation Markers
Thrombin-antithrombin complexes are correlative systemic harbingers of procoagulant activity. 18 PPACK nanoparticle treatment significantly reduced serum thrombin-antithrombin complexes (5.43±0.64 ng/mL, N=5; P=0.0001 versus saline, P=0.032 versus control nanoparticle; Figure 5A ) versus saline (13.32±1.01 ng/mL, N=6) and control nanoparticle (9.96±1.64 ng/mL, N=5; P=NS versus saline).
Because NF-kB is a known driver of endothelial adhesion molecules, we measured soluble vascular cell adhesion molecule 1 (sVCAM-1) levels as biomarkers of activated endothelium in atherosclerosis. 19 ELISA analysis of sVCAM-1 ( Figure 5B ) revealed a modest, but significant decrease in sVCAM-1 with PPACK nanoparticle treatment (1504.88±65.25 ng/mL, N=4) compared with saline treatment (1666.37±12.78 ng/mL, N=5; P=0.029).
Macrophage Responses
Excised aortic arch sections were stained for macrophages ( Figure 6A-6C) , and plaque macrophage content was quantified using ImageJ. We observed no significant difference between treatment groups in terms of overall plaque macrophage content ( Figure 6D ).
Systemic Responses to PPACK Nanoparticle
Activated partial thromboplastin time measurements conducted on serum collected at the time of killing indicated no persistent nonspecific effects of PPACK nanoparticle after the terminal treatment dose 2 to 3 days before killing ( Figure 6E ). Furthermore, no significant difference was observed in serum cholesterol after the PPACK nanoparticle treatment regimen ( Figure 6F ).
Pharmacokinetics
Quantitative 19F spectroscopy was used to estimate the clearance half-life of PPACK nanoparticle in vivo. The half-life of the nanoparticles was determined by measuring the exponential decay of 19 F signal intensity emanating regionally from the tail blood pool ( Figure III , indicative of only modest effects on pharmacokinetics with selected particle surface modifications. The anticipated clearance mechanism for PFC nanoparticle was the reticuloendothelial system as demonstrated by 19 F magnetic resonance imaging of mice postmortem, which depicted 
Discussion
The principal new observation in this work is that focal inhibition of plaque thrombin, and possibly other trypsin-like proteases, in fat-fed ApoE-null mice results in rapid recovery of damaged endothelial barriers and attenuated vascular procoagulant activity in spite of a continued Western diet. These beneficial outcomes were achieved with the use of antithrombin nanoparticles that passively permeated plaque intimal regions after intravenous injection and were focally retained to exert sustained pleiotropic anti-inflammatory effects. Additionally, the progression of atherosclerotic plaque in lesion-prone areas of the ascending aorta was forestalled during the 1 month treatment period. Potential mechanisms for promoting quiescence in activated endothelium related to downregulation of inflammatory NF-kB signaling activity through inhibition of the thrombin-PAR1 signaling are illustrated in Figure 7 .
The direct relationship between thrombotic risk and endothelial barrier disruption ( Figure I and focuses attention on ways to measure and preserve endothelial integrity as a strategic path to the detection and reduction of thrombotic risk. Prior work in our laboratory indicates that the effects of cholesterol feeding elicit both procoagulant effects and barrier disruption only after some time on a sustained high-fat diet: >3 months in ApoE-null mice 11 and >6 months in NZW rabbits 10 . In ApoE-null mice, barrier disruption worsens progressively over time on a high-fat diet, but can resolve rapidly within 2 months after switching to normal chow. 11 Although leaky vasculature and reduced vasodilatory capacity associated with endothelial dysfunction may occur within weeks of inception of an atherogenic diet in the ApoE-null model, 22 the barrier disruption and procoagulant activity identified by our nanoparticle permeability metrics emerge later and may serve as more direct harbingers of thrombotic risk. (NP; B) , and d-phenylalanyl-l-prolyl-l-arginyl chloromethylketone (PPACK)-NP (C) revealed no significant difference in detected plaque macrophages (D) as quantified with ImageJ. E, No significant difference in activated partial thromboplastin time (APTT) between treatment groups, indicating no persisting systemic effect of PPACK-NP on coagulation 2 to 3 days after the penultimate treatment dose. F, No significant difference was observed on serum cholesterol between treatment groups, indicating that therapeutic effects observed occurred without cholesterol lowering as a consequence of nanoparticle treatment.
With respect to the underlying mechanisms responsible for endothelial damage, inflammatory signaling and immunomodulatory events orchestrated by various plaque cell types interacting with activated endothelium have been described in detail. 6 Here we have focused on thrombin as a key instigator of plaque growth and instability contributing to endothelial activation, vessel inflammation, and hypercoagulability, as summarized in Figure 7 . Surprisingly, after an aggressive 1-month treatment period with PPACK nanoparticle after 3 months of initial cholesterol feeding, marked benefits were observed even in the face of persistently elevated serum cholesterol. The role of thrombin not only as a principal prothrombotic agent, but also as an atherogenic molecule is not unexpected given that it drives many of the inflammatory molecules that participate in plaque growth, such as NF-kB, 17 NADPH oxidase, 23 VCAM-1, 24 PDGF, 25 among many others. 6 Thrombin's role as a proinflammatory molecule through the activation of the NF-kB pathway results in numerous downstream effects that accelerate plaque development, cell infiltration, expression of inflammatory molecules, and promotion of hypercoagulability through stimulation and secretion of procoagulant enzymes. 26 Of particular interest is the role of endothelial-specific NF-kB activation in atherogenesis as demonstrated by Gareus et al with the use of genetically engineered conditional knockouts of endothelial NF-kB that markedly suppressed plaque formation in fat-fed ApoE −/− mice. 27 Sun et al achieved similar results by delivering MiR-181b to fat-fed ApoE null mice for 12 weeks to inhibit nuclear translocation of NF-kB in endothelium via importin, even in the face of high cholesterol levels, which is consistent with our present observations. 28 The seminal observations of early upregulation of NF-kB in lesion-prone aortic arch regions by Cybulsky's group 29 raises the interesting speculation of a role for thrombin even at these incipient time points, particularly in the context of previously documented clusters of intense, albeit small, clusters of endothelial apoptosis and replication in these aortic arch regions even in normal subjects. 30, 31 The ability to achieve focal suppression of NF-kB with nanoparticle delivery systems that might abrogate endothelial PAR-1 activation could help to maintain a more quiescent endothelial phenotype (eg, reduced sVCAM; Figure 5B ), preserve barrier integrity, and simultaneously reduce paracrine crosstalk with other inflammatory plaque components.
A pleiotropic response to the suppression of thrombin signaling in diverse cell types that participate in atherogenesis is evidenced by modulation of NF-kB in THP-1 as well as HAEC cells ( Figure 4A -4J; Figure II in the online-only Data Supplement), and our previous reports of reduced platelet content in clots that are produced by vessel injury. 12, 13 Regarding platelet activation, synergistic benefits also could accrue by local inhibition of thrombin-PAR-1 signaling through the NF-kB axis. 32 However, as a potential caveat, it is interesting to note that selective inhibition of NF-kB in macrophage populations has been associated with increased atherosclerosis as contrasted with more specific inhibition of endothelial NF-kB. 33 Although we show that NF-kB may be downregulated in representative human monocyte cell lines in vitro by interrupting thrombin/PAR-1 activation ( Figure 3A ) and in vivo through quantification of pp65 staining in PPACK nanoparticle-treated mice, the exact relationships between macrophages and endothelial signaling and responses to this intervention remain to be defined.
Recent experimental reports have explored the role of thrombin and related coagulation enzymes in promoting atherosclerosis with the use of orally administered antithrombotic agents or genetically modified mice for primary prevention of atherosclerosis. [34] [35] [36] All such studies report significant decreases in overall plaque extent and reduced expression of inflammatory mediators. Secondary prevention clinical trials in patients with acute coronary syndromes using oral antithrombotic agents have shown modest effects on subsequent clinical events related to atherosclerosis progression, but at the risk of significantly increased bleeding. 9 Interestingly, nanoparticle-based thrombin inhibition exhibits similar therapeutic effects to that of the experimental studies mentioned above, but with significantly fewer treatments (12 doses over 4 weeks), no requirement for cholesterol reduction (Figure 6F) , and a more promising safety profile because coagulation parameters and bleeding times have been shown to normalize within 30 to 60 minutes after intravenous injection. 12 We observed no significant change in plaque macrophage content between treatment groups ( Figure 6A-6D ) in contrast to the 50% decrease in plaque macrophages reported by Hara et al after 5 months of Xa inhibition. 37 However, despite our shorter 1-month time window of therapeutic intervention that may not have allowed for reduced plaque macrophage content, our observations of rapid downregulation of NF-kB in macrophage-rich regions and downstream inflammatory markers (TF, thrombin-antithrombin complexes, sVCAM) ( Figure 4E-4H) is consistent with the similar observations of Kadoglou et al in dabigatran-treated ApoE-null mice. 35 These results also accord with previously published data, 38 demonstrating the effect of thrombin and PPACK thrombin in modulating the expression of TF in human saphenous vein endothelial cells, which is thought to be caused by activation of NF-kB. Future work will aim to elucidate the effects of PPACK nanoparticle on plaque healing, with respect to local vascular smooth muscle cell populations and fibrosis in response to therapy over longer follow-up intervals.
The optimal dosing interval for this therapy and the duration of the local effect on barrier integrity and procoagulant activity remain to be defined. Fortunately, the pharmacokinetics (nanoparticle clearance half-life: ≈2 hours; Figure  III in the online-only Data Supplement) is dominated primarily by the nanoparticle itself, with only modest alterations induced by conjugation of the active pharmacological ingredient ( Figure IV in the online-only Data Supplement) or other surface constituents. This minor difference in pharmacokinetics may allow for convenient swapping of alternative anticoagulants, such as bivalirudin, as we have shown previously, 13 while allowing for adequate circulation time to allow for sufficient plaque uptake of nanoparticles, demonstrated in mouse, rabbit, and human samples through prior work in our laboratory. 10, 11 These pharmacokinetic parameters are advantageous for potential clinical applications, as we have shown in mice that nanoparticle clearance through the reticuloendothelial system ( Figure V in the online-only Data Supplement) results in reduction of residual circulating (ie, nontrapped) bioactive conjugated PPACK or bivalirudin moieties within 30 to 60 minutes to a level below that required to alter systemic clotting and bleeding parameters. 12, 13 The potential disadvantage of intravenous nanotherapy also is notable, but there are several clinical scenarios that might benefit from early and aggressive treatment for a period of time before effective cholesterol control could be established. It is also important to note that the particular thrombin inhibitor PPACK may not be entirely specific to thrombin as a serine protease inhibitor, with PPACK exerting inhibitory effects on other trypsinlike proteases, such as Factor Xa. Despite its effects on other proteases, however, PPACK remains a strong inhibitor of thrombin, where the inhibitory effect of PPACK on Xa has been previously shown to be 3 orders of magnitude less than on thrombin. 39 Nevertheless, local inhibition of other coagulation proteases may in fact exert a synergistic but still locally constrained effect in preventing the activation of thrombin.
